# NS Investment

> NS Investment is a VC fund in Seoul backing Biotechnology, Therapeutics and Health Care. See 18 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 18
- Last investment: Jan 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.nsinvest.co.kr/

NS Investment (NSI) is an affiliated firm of Dong-A ST, a leading pharmaceutical company in the Republic of Korea. NSI was established in 2015 to independently manage venture capital funds and serve institutional investors in Korea. NSI is focused on meeting the financial objective of its fund investors. NSI seeks to link Korean investor capitalwith innovative companies beyond its domestic boarders and ultimately link entrepreneurs and science across continents.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 67% |
| Therapeutics | 9 | 50% |
| Health Care | 6 | 33% |
| Medical | 5 | 28% |
| Pharmaceutical | 4 | 22% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 28% |
| Series C | 4 | 22% |
| Seed | 1 | 6% |
| Series A | 1 | 6% |
| Series F | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 11 | 61% |
| South Korea | 1 | 6% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Accent Therapeutics | Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients. | $75M | Series C | Jan 23, 2024 |  |
| Aktis Oncology | Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy.Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. | $84M | Series A | Aug 25, 2022 |  |
| Aspen Neuroscience | Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $147.5M | Series B | May 09, 2022 |  |
| DAAN Biotherapeutics | DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $4.1M | Seed | Mar 28, 2022 |  |
| Dewpoint Therapeutics | Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates. | $150M | Series C | Feb 03, 2022 |  |
| Maze Therapeutics | Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $190M | Venture - Series Unknown | Jan 10, 2022 |  |
| Shoreline Biosciences | Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $140M | Series B | Nov 02, 2021 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M | Series B | Oct 21, 2021 |  |
| Immunitas Therapeutics | Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $58M | Series B | Aug 18, 2021 |  |
| Sonoma Biotherapeutics | Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $265M | Series B | Aug 04, 2021 |  |

10 of 18 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 7 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 6 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 6 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 4 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does NS Investment invest in?

NS Investment invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series C stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did NS Investment last invest?

The most recent investment recorded for NS Investment closed in Jan 2024. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co